A5033464950- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Esophageal Cancer Research and Treatment
- Complement system in diseases
- Immune cells in cancer
- Cancer Research and Treatments
- Gut microbiota and health
- Single-cell and spatial transcriptomics
- T-cell and B-cell Immunology
- Cell Adhesion Molecules Research
Rockefeller University
2023-2024
Institut de Pharmacologie et de Biologie Structurale
2021-2023
Université de Toulouse
2022-2023
Centre National de la Recherche Scientifique
2022-2023
Université Toulouse III - Paul Sabatier
2022-2023
Recruitment of lymphocytes into tumors is critical for anti-tumor immunity and efficacious immunotherapy. We show in murine models that tumor-associated high endothelial venules (TA-HEVs) are major sites lymphocyte entry at baseline upon treatment with anti-PD-1/anti-CTLA-4 immune checkpoint blockade (ICB). TA-HEV cells (TA-HECs) derive from post-capillary venules, co-express MECA-79+ HEV sialomucins E/P-selectins, associated homing infiltration various T cell subsets. Intravital microscopy...
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but mechanisms underlying their immunosuppressive effects remain unknown. By inducing down-regulation mucosal addressin adhesion molecule (MAdCAM-1) ileum, post-ABX gut recolonization by Enterocloster species drove emigration enterotropic α4β7+CD4+ regulatory T 17 cells into tumor. These deleterious ABX were mimicked oral gavage species, genetic deficiency, or antibody-mediated...
Abstract Preclinical murine data indicate that fragment crystallizable (Fc)-dependent depletion of intratumoral regulatory T cells (Treg) is a major mechanism action anti–CTLA-4. However, the two main antibodies administered to patients (ipilimumab and tremelimumab) do not recapitulate these effects. Here, we investigate underlying mechanisms responsible for limited Treg observed with therapies. Using an immunocompetent model humanized CTLA-4 Fcγ receptors (FcγR), show ipilimumab...
Here, we present a protocol for flow cytometry analysis of endothelial cells (ECs) and CD8+ T in murine tumor models, at baseline after cancer immunotherapy with anti-PD-1/anti-CTLA-4 antibodies. We provide gating strategies identification specific cell subsets including ECs from tumor-associated high venules (TA-HEVs), stem-like, terminally exhausted cells. This represents valuable tool the rare critical roles antitumor immunity. For complete details on use execution this protocol, please...
<p>Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies</p>
<p>Antitumor activity of Fc-engineered murine anti-CCR8 antibodies</p>
<p>Antitumor activity of Fc-engineered murine anti-CCR8 antibodies</p>
<p>Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc</p>
<p>Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies</p>
<div>Abstract<p>Preclinical murine data indicate that fragment crystallizable (Fc)-dependent depletion of intratumoral regulatory T cells (Treg) is a major mechanism action anti–CTLA-4. However, the two main antibodies administered to patients (ipilimumab and tremelimumab) do not recapitulate these effects. Here, we investigate underlying mechanisms responsible for limited Treg observed with therapies. Using an immunocompetent model humanized CTLA-4 Fcγ receptors (FcγR), show...
<div>Abstract<p>Preclinical murine data indicate that fragment crystallizable (Fc)-dependent depletion of intratumoral regulatory T cells (Treg) is a major mechanism action anti–CTLA-4. However, the two main antibodies administered to patients (ipilimumab and tremelimumab) do not recapitulate these effects. Here, we investigate underlying mechanisms responsible for limited Treg observed with therapies. Using an immunocompetent model humanized CTLA-4 Fcγ receptors (FcγR), show...
<p>Legends</p>
<p>Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc</p>
<p>Legends</p>
<p>Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors</p>
<p>Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors</p>
Abstract Introduction: The CD40-CD40L pathway is crucial for activating antigen-presenting cells and initiating tumor-specific T cell responses across various malignancies. However, prior agonistic anti-CD40 antibodies have encountered limited clinical success significant toxicity. Our previous studies demonstrate that interactions between the antibody Fc domain inhibitory Fc-gamma receptor FcγRIIB are critical efficient CD40 multimerization enhanced antitumor activity. To optimize this...